Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

Dysfunctional Labor Clinical Trial

Official title:

Placebo-Controlled Randomized Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Dysfunctional Labor

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00315913
• Other study ID #: HS #2004-3997
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 2004
• Est. completion date: March 2008

Study information

• Verified date: February 2019
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether propranolol is better than oxytocin for the treatment of labor abnormalities. The endpoint is the rate of vaginal delivery experienced by women receiving prolonged oxytocin versus propranolol.

Description:

This trial was designed to test if propranolo can reduce the c section rate for dysfuctional labor. Due to stringent inclution and exclusion criteria and low enrollment the study was closed.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be term pregnancy (> 37 weeks)

• Vertex presentation

• Active labor (4-5 centimeters dilated)

Exclusion Criteria:

• Heart disease

• Diabetes

• Currently taking propranolol

• Contraindications to labor or vaginal delivery

• Multiple gestations

• Preterm

• Chorioamnionitis

Related Conditions & MeSH terms

• Dysfunctional Labor
• Dystocia

Intervention

Drug:
• Propranolol
IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg

Other:
• IV Placebo
IV Saline Solution

Locations

Country	Name	City	State
United States	Long Beach Memorial Medical Center	Long Beach	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Irvine

Country where clinical trial is conducted

United States,